Vaccinex is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Co. is utilizing its semaphorin 4D (SEMA4D) antibody platform and its knowledge of SEMA4D biology to develop its primary product candidate, pepinemab (also known as VX15/2503). Co. focuses on the development of pepinemab for the treatment of certain cancer indications, in particular, non-small cell lung cancer and head and neck squamous cell carcinoma as well as neurodegenerative diseases, including Huntington's disease and Alzheimer's disease. The VCNX stock yearly return is shown above.
The yearly return on the VCNX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the VCNX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|